Gut bacteria may supercharge cancer immunotherapy, new trial hints
NCT ID NCT03686202
First seen Feb 15, 2026 · Last updated May 09, 2026 · Updated 12 times
Summary
This study explores whether a fecal microbiome treatment called MET-4 can make immunotherapy more effective for people with advanced solid tumors. About 65 participants will receive MET-4 alongside standard immunotherapy or immunotherapy alone. The goal is to see if MET-4 is safe and can increase helpful gut bacteria linked to better treatment response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALL SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.